MedTrace Logo

Polypharmacy, Safety, and Medication Adherence in Patients With Chronic Heart Failure With Reduced and Mildly Reduced Ejection Fraction

NCT07640854 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 130

Last updated 2026-06-16

No results posted yet for this study

Summary

This prospective registry study (FARAON) aims to assess the prevalence, structure, safety profile, and dynamics of polypharmacy, as well as its association with medication adherence, quality of life, and clinical outcomes in multimorbid patients with HFrEF and HFmrEF, aiming to identify potentially inappropriate prescribing (over/mis/underprescribing) and determine factors linked to low adherence and adverse events.

Conditions

  • Chronic Heart Failure With Reduced and Mildly Reduced Ejection Fraction (HFrEF and HFmrEF)

Sponsors & Collaborators

  • National Medical Research Center for Therapy and Preventive Medicine

    lead OTHER_GOV

Principal Investigators

  • Sergey Martsevich, M.D., Professor · National Medical Research Centre for Therapy and Preventive Medicine, Moscow, Russia

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-01-20
Primary Completion
2027-01-31
Completion
2027-01-31

Countries

  • Russia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07640854 on ClinicalTrials.gov